as noted by new atlas promising phase 2 clinical results trials of a drug that lowers cholesterol. the drug, evinacumab, could reduce cholesterol levels by about half in patients with extremely high cholesterol compared to placebo.
when the level of low-density lipoproteins ("bad cholesterol", ldl) rises, hypercholesterolemia develops, threatening heart attacks, stroke and other cardiovascular disorders. standard therapy involves the use of statins (acting on the liver protein pcsk9) and drugs that reduce the absorption of cholesterol in the small intestine. but such a scheme does not always help.
while existing drugs target the ldl receptor gene, evinacumab uses a different mechanism to control cholesterol levels. it is a human monoclonal antibody that inhibits angiopoietin-like protein 3 (angplt3) and lowers cholesterol through an ldl receptor-independent pathway. genetic studies have shown that people with low angptl3 levels have very low ldl concentrations and rarely suffer from atherosclerotic abnormalities.
in the second phase of trials of evinacumab, 272 patients with hypercholesterolemia participated. the drug and placebo were administered subcutaneously or intravenously at different doses and at different intervals. after 16 weeks, participants who received weekly subcutaneous injections of 450 milligrams of evinacumab had ldl levels 56% lower than those in the placebo group. the group that received 300 milligrams per week saw a 52.9% decrease, and the group that received 300 milligrams every two weeks saw a 38.5% decrease.
in the group receiving intravenous 15 milligrams of evinacumab per kilogram of body weight, the level of cholesterol was approximately 50.5% lower than in the placebo group. the introduction of 5 milligrams reduced the rates by 24.2%.